# Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

> **NCT01857453** · PHASE2 · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 97 (estimated)

## Conditions studied

- Medulloblastoma

## Interventions

- **DRUG:** carboplatine
- **DRUG:** Etoposide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT01857453
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04-10
- **Primary completion:** 2018-12
- **Final completion:** 2021-12
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2018-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857453, "Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01857453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*